How to Dose Cariprazine for MDD Augmentation?

Major depressive disorder (MDD) remains a significant global health challenge, affecting millions of individuals and often leading to substantial impairment in daily functioning. While a variety of antidepressants are available, not all patients respond adequately to first-line treatment options. 

This has led to growing interest in augmentation strategies, which involve adding an additional medication to enhance the effectiveness of the primary treatment. One such potential augmentation agent is cariprazine, an atypical antipsychotic initially approved for the treatment of schizophrenia and bipolar disorder.

Understanding how to appropriately dose cariprazine is crucial for healthcare professionals looking to optimize treatment outcomes while minimizing side effects.

Watch our YouTube video summarizing this topic:

HOW TO DOSE CARIPRAZINE FOR MDD AUGMENTATION?

DETAILED LECTURE FOR ACADEMY MEMBERS:

MDD Augmentation: Antipsychotics

FOR ACADEMY MEMBERS
ACADEMY

JOIN EMAIL NEWSLETTER (FREE):

INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?

JOIN ACADEMY MEMBERSHIP:

This is a closed membership for medical professionals only.

  • 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. 
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
  • Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
  • Goal: is to have all important clinically relevant topics in one place for ease of access.
GENERAL
$ 99/YR
  •  
STUDENTS
$ 75/YR
  •  

DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.

Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com

© 2024 All Rights Reserved.

Related Articles

Responses

Your email address will not be published. Required fields are marked *